270 related articles for article (PubMed ID: 22041253)
21. Fields of muscular and anhidrotic effects of 2 botulinum toxin-A commercial preparations: a prospective, double-blind, randomized, multicenter study.
Hexsel D; Soirefmann M; Porto MD; Siega C; Schilling-Souza J; Rodrigues TC
Dermatol Surg; 2015 Jan; 41 Suppl 1():S110-8. PubMed ID: 25548839
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
[TBL] [Abstract][Full Text] [Related]
23. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
Alimohammadi M; Andersson M; Punga AR
Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
[TBL] [Abstract][Full Text] [Related]
24. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
25. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
[TBL] [Abstract][Full Text] [Related]
26. Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.
Nestor M; Ablon G; Pickett A
Aesthet Surg J; 2017 May; 37(suppl_1):S20-S31. PubMed ID: 28388717
[TBL] [Abstract][Full Text] [Related]
27. Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions.
Kranz G; Sycha T; Voller B; Gleiss A; Schnider P; Auff E
Dermatol Surg; 2006 Jul; 32(7):886-90. PubMed ID: 16875469
[TBL] [Abstract][Full Text] [Related]
28. Muscle atrophy beyond the clinical effect after a single dose of OnabotulinumtoxinA injected in the procerus muscle: a study with magnetic resonance imaging.
Koerte IK; Schroeder AS; Fietzek UM; Borggraefe I; Kerscher M; Berweck S; Reiser M; Ertl-Wagner B; Heinen F
Dermatol Surg; 2013 May; 39(5):761-5. PubMed ID: 23379599
[TBL] [Abstract][Full Text] [Related]
29. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion.
Flynn TC; Clark RE
Dermatol Surg; 2003 May; 29(5):519-22; discussion 522. PubMed ID: 12752521
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
Monheit G; Carruthers A; Brandt F; Rand R
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
[TBL] [Abstract][Full Text] [Related]
31. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis.
Rystedt A; Swartling C; Färnstrand C; Naver H
Acta Derm Venereol; 2008; 88(5):458-61. PubMed ID: 18779882
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study.
Kranz G; Paul A; Voller B; Posch M; Windischberger C; Auff E; Sycha T
Br J Dermatol; 2011 Jan; 164(1):176-81. PubMed ID: 21039405
[TBL] [Abstract][Full Text] [Related]
33. A pilot study on the effect of epinephrine on botulinum toxin treatment for periorbital rhytides.
Hantash BM; Gladstone HB
Dermatol Surg; 2007 Apr; 33(4):461-8. PubMed ID: 17430381
[TBL] [Abstract][Full Text] [Related]
34. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
Schlessinger J; Monheit G; Kane MA; Mendelsohn N
Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
[TBL] [Abstract][Full Text] [Related]
35. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the spread of three botulinum toxin type A preparations.
Kerscher M; Roll S; Becker A; Wigger-Alberti W
Arch Dermatol Res; 2012 Mar; 304(2):155-61. PubMed ID: 22002325
[TBL] [Abstract][Full Text] [Related]
37. Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis.
Spencer JM; Gordon M; Goldberg DJ
J Cosmet Laser Ther; 2002 Mar; 4(1):19-23. PubMed ID: 12079633
[TBL] [Abstract][Full Text] [Related]
38. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Rubin M; Dover J; Maas C; Nestor M
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
[TBL] [Abstract][Full Text] [Related]
39. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
40. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
Carruthers A; Carruthers J; Said S
Dermatol Surg; 2005 Apr; 31(4):414-22; discussion 422. PubMed ID: 15871316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
